ProSomnus (NASDAQ: OSA) is the leading manufacturer of precision, mass-customized patient preferred, Oral Appliance Therapy medical devices for the treatment of OSA (Obstructive Sleep Apnea). OSA affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.

ProSomnus’s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure CPAP) therapy, and lead to more effective and patient-preferred outcomes. With more than 200,000 patients treated, ProSomnus devices are the most prescribed precision Oral Appliance Therapy in the U.S.

Join our innovative team of individuals, dedicated to delivering providers and their patients the patient preferred OSA therapy resulting in more effective treatment and superior patient compliance.